Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy firm Biocept said today that it has closed a previously announced public stock offering, raising net proceeds of approximately $13.3 million after deducting fees and offering expenses from a total sale of $14.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.